75693-15-1

Usage

Uses

Due to the limited information available on 7-Bromo-1,2,3,4-tetrahydronaphthalen-1-ol, it is challenging to provide a comprehensive list of its applications. However, based on its chemical structure and the properties of similar compounds, we can infer potential uses in the following areas:
Used in Chemical Synthesis:
7-Bromo-1,2,3,4-tetrahydronaphthalen-1-ol may be used as an intermediate or reagent in the synthesis of more complex organic compounds, particularly those requiring a tetralin or brominated structure. Its hydroxyl group could be involved in various reactions, such as esterification, etherification, or condensation, to form new molecules with different properties and applications.
Used in Pharmaceutical Research:
Given its structural features, 7-Bromo-1,2,3,4-tetrahydronaphthalen-1-ol could be a candidate for pharmaceutical research, potentially serving as a lead compound in the development of new drugs. Its hydroxyl and bromine groups may allow for modifications to improve its biological activity, selectivity, or pharmacokinetic properties.
Used in Material Science:
7-Bromo-1,2,3,4-tetrahydronaphthalen-1-ol's aromatic and brominated nature may make it suitable for use in the development of new materials, such as polymers, coatings, or adhesives, where its chemical stability and potential reactivity could be advantageous.

Upstream product

• 32281-97-3 7-bromo-3,4-dihydro-2H-naphthalen-1-one 

Downstream Products

• 75693-17-3 bromo-7 dihydro-3,4 naphthalene 
• 1049001-69-5 Br^(1-)*C₂₈H₂₅BrP⁽¹⁺⁾ 
• 32281-97-3 7-bromo-3,4-dihydro-2H-naphthalen-1-one 
• 1617524-93-2 C₁₆H₁₄ 
• 2717-47-7 1,2-dihydro-6-methylnaphthalene 
• 22531-20-0 6-ethyltetralin 
• 42775-77-9 6-Propyl-tetralin 
• 1680-51-9 6-methyl-1,2,3,4-tetrahydronaphthalene 
• 75693-20-8 7-bromo-1,2-epoxy-1,2,3,4-tetrahydronaphthalene 

Relevant academic research and scientific papers

Development of Novel Phosphino-Oxazoline Ligands and Their Application in Asymmetric Alkynlylation of Benzylic Halides

A new set of stereochemically diverse phosphino-oxazoline ligands derived from simple L-amino acids and 2-(diphenylphosphaneyl)benzoic acid were developed. Those mono anionic tridentated N,N,P-ligands promote the Cu-catalyzed enantioselective radical coupling of terminal alkynes with a broad range of benzylic halides including benzo-fused cyclic α-halides and α-silyl benzyl halides in high yield and excellent enantioselectivity under mild reaction conditions. With multi distinct sites for structural modification, a diverse pool of chiral N,N,P-ligands is readily accessed, allowing for rapid optimization of the ligand structure for a specific substrate. Notably, the enantioselective alkynlylation of benzylic halides bonds in benzo-cyclic molecules has also been realized for the first time.

Chemoselective Oxidation of Equatorial Alcohols with N-Ligated λ3-Iodanes

The site-selective and chemoselective functionalization of alcohols in complex polyols remains a formidable synthetic challenge. Whereas significant advancements have been made in selective derivatization at the oxygen center, chemoselective oxidation to the corresponding carbonyls is less developed. In cyclic systems, whereas the selective oxidation of axial alcohols is well known, a complementary equatorial selective process has not yet been reported. Herein we report the utility of nitrogen-ligated (bis)cationic λ3-iodanes (N-HVIs) for alcohol oxidation and their unprecedented levels of selectivity for the oxidation of equatorial over axial alcohols. The conditions are mild, and the simple pyridine-ligated reagent (Py-HVI) is readily synthesized from commercial PhI(OAc)2 and can be either isolated or generated in situ. Conformational selectivity is demonstrated in both flexible 1,2-substituted cyclohexanols and rigid polyol scaffolds, providing chemists with a novel tool for chemoselective oxidation.

3-(2,3-DIHYDRO-1H-INDEN-5-YL)PROPANOIC ACID DERIVATIVES AND THEIR USE AS NRF2 REGULATORS

The present invention relates to compounds of Formula (I), and Formula (II), wherein B is benzotriazolyl, phenyl, triazolopyridinyl, or -(CH2)2-triazolyl each of which may be unsubstituted or substituted by 1, 2, or 3 substituents independently chosen from -C1-3 alkyl, -O-C1-3 alkyl, CN, - (CH2)2-O-(CH2)2-OR4 and halo; and D is -C(O)OH, -C(O)NHSO2CH3, -SO2NHC(O)CH3, 5-(trifluoromethyl)-4H-1,2,4-triazol-2-yl, or tetrazolyl; and their use as NRF2 regulators.

(Poly)cationic λ3-Iodane-Mediated Oxidative Ring Expansion of Secondary Alcohols

Herein, a simplified approach to the synthesis of medium-ring ethers through the electrophilic activation of secondary alcohols with (poly)cationic λ3-iodanes (N-HVIs) is reported. Excellent levels of selectivity are achieved for C–O bond migration over established α-elimination pathways, enabled by the unique reactivity of a novel 2-OMe-pyridine-ligated N-HVI. The resulting hexafluoroisopropanol (HFIP) acetals are readily derivatized with a range of nucleophiles, providing a versatile functional handle for subsequent manipulations. The utility of this methodology for late-stage natural product derivatization was also demonstrated, providing a new tool for diversity-oriented synthesis and complexity-to-diversity (CTD) efforts. Preliminary mechanistic investigations reveal a strong effect of alcohol conformation on the reactive pathway, thus providing a predictive power in the application of this approach to complex molecule synthesis.

NRF2 REGULATORS

The present invention relates to aryl analogs, pharmaceutical compositions containing them and their use as Nrf2 regulators.

Condensed derivatives of imidazole useful as pharmaceuticals

The invention relates to the compounds (I) and their acids and bases salts: wherein: the dotted line indicates a double bond; X is N or C-R1 and Y is N or C-R2, X and Y not being simultaneously N; A is selected from the group consisting of phenyl, naphthyl and (5-11) membered monocyclic or bicyclic unsaturated cycle or heterocycle possibly substituted as defined in the application, and A can also comprise either a further (4-7) membered heterocycle, said heterocycle being a monocycle, fused, saturated or unsaturated, the polycyclic system then comprising up to 14 members and up to 5 heteroatoms selected from N, O and S; B is Hydrogen or a substituent as defined in the application, or B is a (4-10) membered mono or bicyclic saturated or unsaturated heterocycle containing 1-3 heteroatoms selected from N, O and S, and possibly substituted as defined in the application; B not being Hydrogen when X is N and Y is C-R2; R1 is Hydrogen or a substituent as defined in the application; B and R1 cannot be simultaneously Hydrogen; R2 is Hydrogen or Halogen; their preparation, their use in the antibacterial prevention and therapy, alone or in association with antibacterials, antivirulence agents or drugs reinforcing the host innate immunity, and pharmaceutical compositions and associations containing them.

Catalytic asymmetric intermolecular bromoesterification of unfunctionalized olefins

An asymmetric intermolecular bromoesterification of unfunctionalized olefins catalyzed by (DHQD)2PHAL is described. Optically active bromoesters can be obtained with up to 92% ee.

Direct oxidative allylic and vinylic amination of alkenes through selenium catalysis

Bringing "N" into the game: The direct chemoselective nitrogenation of unactivated alkenes can be achieved through oxidative selenium catalysis (see scheme). This method provides a broad variety of allylic imides in yields of up to 89 % using N-fluorobenzenesulfonimide (NFSI) as the terminal oxidant and nitrogen source. Furthermore, an unprecedented selenium-catalyzed vinylic C(sp2)-H nitrogenation was discovered. Copyright

Cathepsin S Inhibitor Compounds

The present invention provides a compound of Formula (I): or a pharmaceutically acceptable salt thereof. Also, the present invention provides a pharmaceutical composition comprising a compound of Formula (I) or a pharmaceutically acceptable salt thereof with a pharmaceutically acceptable diluent or carrier. The present invention further provides methods for treating abdominal aortic aneurysm, plaque instability, atherosclerosis, or autoimmune disorders such as rheumatoid arthritis, psoriasis, and lupus comprising administering a therapeutically effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof or a pharmaceutical composition comprising a compound of Formula (I) or pharmaceutically acceptable salt thereof and a pharmaceutically acceptable diluent or carrier.

FUNCTIONALLY SELECTIVE ALPHA2C ADRENORECEPTOR AGONISTS

In its many embodiments, the present invention provides a novel class of biaryl compounds as inhibitors of ?2C adrenergic receptor agonists, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of